Related Experiment Video
Updated: Jul 12, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Continuous Intraperitoneal Insulin Infusion for People With Type 1 Diabetes: A Literature Review and International
Nick Oliver1, Bernhard Gehr2, Rayhan Lal3,4
1Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Diabetes, Obesity & Metabolism
|July 9, 2026
Summary
Continuous intraperitoneal insulin infusion offers comparable or better glucose control than subcutaneous methods for type 1 diabetes management. This approach may reduce hypoglycemia frequency, especially when subcutaneous insulin fails or in cases of severe needle phobia.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Diabetes Management
Background:
- Optimal type 1 diabetes (T1D) management aims for glucose targets without hypoglycemia.
- Advances like structured education, advanced insulin regimens, and continuous glucose monitoring aid T1D management.
- Barriers persist in achieving optimal T1D control.
Purpose of the Study:
- To review intraperitoneal insulin infusion (IPII) technology for T1D.
- To evaluate IPII's risks, benefits, and compare it to subcutaneous insulin infusion (CSII).
- To provide an expert position statement on IPII for T1D.
Main Methods:
- Review of current IPII technology.
- Analysis of glucose outcomes and hypoglycemia frequency with IPII versus CSII.
- Expert consensus on IPII indications and considerations.
Main Results:
- IPII demonstrates comparable or superior glucose control to CSII.
- IPII may decrease the incidence of hypoglycemia, including severe episodes.
- IPII is a viable option for T1D patients with CSII failure (e.g., lipodystrophy, allergy, resistance) or severe needle phobia.
Conclusions:
- IPII is a potential treatment modality for select T1D patients.
- Consider IPII for those with CSII failure, severe needle phobia, or awaiting transplantation.
- IPII offers an alternative for optimizing glucose control and reducing hypoglycemia in T1D.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...